A Phase I/ II Trial of Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
Phase of Trial: Phase I/II
Latest Information Update: 13 Nov 2018
At a glance
- Drugs Pazopanib (Primary) ; Bevacizumab
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2018 Planned primary completion date changed from 13 Oct 2018 to 13 Dec 2018.
- 31 Aug 2018 Biomarkers information updated
- 11 Jun 2018 Planned primary completion date changed from 5 May 2018 to 13 Oct 2018.